Novel gene therapy PS-002 targets podocytes in IgA nephropathy

The gene therapy, called PS-002, uses a modified virus to treat kidney cells called podocytes. Administration of PS-002 in a mouse model of IgA nephropathy reduced signs of kidney dysfunction, lowered complement deposition, and ameliorated kidney scarring and other structural characteristics of kidney disease. In pigs, treatment with PS-002 resulted in elevated and prolonged gene expression in kidney tissues, with no safety issues.

Study: "Podocyte gene therapy enables glomerular complement modulation for IgA Nephropathy (IgAN) Treatment"

Source:

American Society of Nephrology